This project is to develop long-acting injectable (LAI) formulations of next-generation diarylquinolines (DARQs) with and without possible companion agents for tuberculosis (TB) preventive therapy (TPT) and for use during the continuation phase of active TB treatment. The ultimate goal of this NIH funded project is to develop a ‘one-shot’ DARQ LAI treatment for TPT as well an optimised LAI-based treatment strategy for use in the continuation phase of active TB treatment, each with a sufficient data package to enable an FDA application.